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Background:  Medication persistence following acute myocardial infarction (AMI) is an important opportunity to improve patient outcomes. 
While cardiac rehabilitation (CR) after AMI fosters healthy behaviors, it is unknown whether CR participation improves medication persistence. We 
examined the association between CR participation and medication persistence in a large cohort of post-AMI patients.
Methods:  Among 6,838 patients enrolled in 2 US multi-center, prospective registries of AMI patients (PREMIER and TRIUMPH), 2498 were referred 
to CR. We derived a propensity-matched cohort allowing up to a 1 to 2 match of patients referred to CR who did or did not attend 1 or more CR 
sessions by the time of their 6 month follow-up interview (n=1,814; 873 in the CR group and 941 in the no CR group). The primary outcome was 
persistence to cardiac medications (aspirin, beta-blockers, statins, angiotensin converting enzyme inhibitors (ACEI)/angiotensin receptor blockers 
(ARB), thienopyridines) at 6 months among those prescribed these medications at discharge.
Results:  At 6 months, patients participating in 1 or more CR sessions (range 1 to 31) were more likely to be persistent with beta-blockers (OR 
1.42, 95% CI 1.0-2.0) and statins (OR 1.72, 95% CI 1.2-2.4) but not aspirin (OR 1.3, 95% CI 0.92-1.7), ACEI/ARB (OR 0.99, 95% CI 0.69-1.4) 
or thienopyridines (OR 1.0, 95% CI 0.74-1.3). Compared to the lowest quartile, those in the higher quartiles of CR sessions attended had better 
persistence to several classes of medications: ACEI/ARB, 85.1% vs 74.8% (trend p=0.024); thienopyridines, 81.7% vs. 71.2% (trend p=0.033); and 
beta-blockers, 91.4% vs. 83.6% (trend p=0.054), suggesting a dose-response relationship between CR and medication persistence.
Conclusion: Participation in CR is associated with greater persistence to important secondary prevention medications after discharge from an AMI, 
with even greater persistence among those participating in more CR sessions. These findings suggest a potential explanation for the cardiovascular 
benefits of CR and highlight the need for additional studies to assess whether CR improves medication persistence.
